The Manufacturers Life Insurance Company Buys New Stake in Odyssey Therapeutics, Inc. $ODTX

The Manufacturers Life Insurance Company purchased a new stake in Odyssey Therapeutics, Inc. (NASDAQ:ODTX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 32,125 shares of the company’s stock, valued at approximately $601,000.

Separately, Citadel Advisors LLC purchased a new position in shares of Odyssey Therapeutics in the 2nd quarter valued at about $4,162,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ODTX shares. HC Wainwright started coverage on Odyssey Therapeutics in a report on Thursday, August 27th. They issued a “buy” rating and a $44.00 price target for the company. Wedbush started coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $30.00 target price for the company. Zacks Research raised shares of Odyssey Therapeutics to a “hold” rating in a research report on Wednesday, June 3rd. Cantor Fitzgerald began coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “overweight” rating for the company. Finally, Wall Street Zen downgraded shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 20th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Odyssey Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $35.75.

Odyssey Therapeutics Trading Down 1.5%

NASDAQ ODTX opened at $24.26 on Tuesday. The firm has a market capitalization of $1.17 billion and a price-to-earnings ratio of -3.58. Odyssey Therapeutics, Inc. has a one year low of $15.10 and a one year high of $29.05. The company has a fifty day simple moving average of $21.43.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. Research analysts anticipate that Odyssey Therapeutics, Inc. will post -5.99 EPS for the current year.

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, structural biology, medicinal chemistry and other drug-discovery technologies to identify therapies designed to target specific disease mechanisms.

Odyssey’s research programs are centered on small-molecule therapeutics intended to modulate immune pathways and address conditions with significant unmet medical needs.